(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are BENEVOLENTAI, PHOTOCURE, and ADOCIA.

Financial Asset	Price	Change	Updated (EST)
BENEVOLENTAI (BAI.AS)	0.60	9.09%	2024-05-13 12:01:06
PHOTOCURE (PHO.OL)	61.40	6.23%	2024-05-13 12:42:23
ADOCIA (ADOC.PA)	9.11	5.56%	2024-05-13 12:45:19
AKER HORIZONS (AKH.OL)	3.20	4.98%	2024-05-13 12:24:42
TEKNA HOLDING (TEKNA.OL)	5.96	4.56%	2024-05-13 12:44:01
NYXOAH (NYXH.BR)	8.50	4.42%	2024-05-13 12:21:01
MPC CONTAINER SHIP (MPCC.OL)	19.73	4.09%	2024-05-13 12:41:13
BEVER HOLDING (BEVER.AS)	2.56	4.07%	2024-05-13 12:01:10
ULTIMOVACS (ULTI.OL)	7.21	4.04%	2024-05-13 12:44:15
DGB GROUP N.V. (DGB.AS)	0.53	3.92%	2024-05-13 12:02:00

The three biggest losers today are NAI ORD SHARES, PROSAFE, and NEPI ROCKCASTLE.

Financial Asset	Price	Change	Updated (EST)
NAI ORD SHARES (NAI.AS)	8.30	-9.78%	2024-05-13 12:03:29
PROSAFE (PRS.OL)	30.85	-8.05%	2024-05-13 12:42:28
NEPI ROCKCASTLE (NRP.AS)	6.10	-6.15%	2024-05-13 12:03:32
FUT.CLUBE PORTO (FCP.LS)	1.60	-5.88%	2024-05-13 12:23:22
ARCTICZYMES TECHNO (AZT.OL)	22.50	-5.86%	2024-05-13 12:24:51
BERGENBIO (BGBIO.OL)	0.13	-5.62%	2024-05-13 12:25:16
ADUX (ADUX.PA)	1.34	-4.64%	2024-05-13 12:45:23
INTEROIL EXPL PROD (IOX.OL)	1.90	-4.52%	2024-05-13 12:40:37
VISTIN PHARMA (VISTN.OL)	22.60	-4.24%	2024-05-13 12:44:18
EDP (EDP.LS)	3.69	-4.08%	2024-05-13 12:23:15

Winners today

1. BENEVOLENTAI (BAI.AS)

9.09% Price Change

BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

AEX-Index ended the session with BENEVOLENTAI rising 9.09% to €0.60 on Monday, after five consecutive sessions in a row of losses. AEX-Index jumped 0.14% to €911.91, after two sequential sessions in a row of gains, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-0.62.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.01%.

Volume

Today’s last reported volume for BENEVOLENTAI is 5809 which is 60.61% below its average volume of 14751.

Moving Average

BENEVOLENTAI’s worth is way under its 50-day moving average of €0.70 and way below its 200-day moving average of €0.84.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BENEVOLENTAI’s stock is considered to be overbought (>=80).

Revenue Growth

Year-on-year quarterly revenue growth declined by 64.4%, now sitting on 7.33M for the twelve trailing months.

More news about BENEVOLENTAI.

2. PHOTOCURE (PHO.OL)

6.23% Price Change

Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with PHOTOCURE rising 6.23% to €61.40 on Monday while Oslo Børs Benchmark Index_GI dropped 0.16% to €1,416.45.

Earnings Per Share

As for profitability, PHOTOCURE has a trailing twelve months EPS of kr0.04.

PE Ratio

PHOTOCURE has a trailing twelve months price to earnings ratio of 1535. Meaning, the purchaser of the share is investing kr1535 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.06%.

Volume

Today’s last reported volume for PHOTOCURE is 183307 which is 119.21% above its average volume of 83619.

Volatility

PHOTOCURE’s last week, last month’s, and last quarter’s current intraday variation average was 0.77%, 0.07%, and 2.07%.

PHOTOCURE’s highest amplitude of average volatility was 2.16% (last week), 1.71% (last month), and 2.07% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 36.8%, now sitting on 500.66M for the twelve trailing months.

Yearly Top and Bottom Value

PHOTOCURE’s stock is valued at kr61.40 at 22:40 EST, way under its 52-week high of kr71.90 and way higher than its 52-week low of kr40.70.

More news about PHOTOCURE.

3. ADOCIA (ADOC.PA)

5.56% Price Change

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of prandial insulin with pramlintide, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and AdoGel Sema for the long-term delivery of therapeutic agents. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

CAC 40 ended the session with ADOCIA rising 5.56% to €9.11 on Monday, following the last session’s upward trend. CAC 40 dropped 0.12% to €8,209.28, after five consecutive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, ADOCIA has a trailing twelve months EPS of €-1.9.

Moving Average

ADOCIA’s value is above its 50-day moving average of €9.07 and way higher than its 200-day moving average of €6.63.

More news about ADOCIA.

4. AKER HORIZONS (AKH.OL)

4.98% Price Change

Aker Horizons ASA, through its subsidiaries, develops and invests in renewable energy and green technology private and public companies worldwide. The company offers modular and capture units for reducing and removing carbon dioxide emissions of various industries, including the cement, bio and waste-to-energy, gas-to-power and blue hydrogen segments. It also develops, owns, and operates industrial-scale hydrogen projects for industries, such as shipping, steel, and fertilizers; and operates onshore and offshore wind and solar power generation. The company was incorporated in 2020 and is based in Lysaker, Norway. Aker Horizons ASA operates as a subsidiary of Aker Capital AS.

Oslo Børs Benchmark Index_GI ended the session with AKER HORIZONS jumping 4.98% to €3.20 on Monday, after four sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI dropped 0.16% to €1,416.45, after five sequential sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, AKER HORIZONS has a trailing twelve months EPS of kr-6.49.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -81.14%.

Moving Average

AKER HORIZONS’s worth is way below its 50-day moving average of kr6.41 and way under its 200-day moving average of kr10.38.

Volatility

AKER HORIZONS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.66%, a negative 0.51%, and a positive 2.91%.

AKER HORIZONS’s highest amplitude of average volatility was 1.66% (last week), 3.39% (last month), and 2.91% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AKER HORIZONS’s stock is considered to be overbought (>=80).

Volume

Today’s last reported volume for AKER HORIZONS is 4330760 which is 36.96% above its average volume of 3161940.

More news about AKER HORIZONS.

5. TEKNA HOLDING (TEKNA.OL)

4.56% Price Change

Tekna Holding ASA engages in the development, manufacture, and sale of micron and nano powders, and plasma process solutions in North America, Europe, Asia, and internationally. The company offers spherical powders, such as titanium, nickel, and aluminum alloys, as well as tungsten and tantalum; and nanopowders, including nickel, silicon, and copper nanopowders, as well as boron nitride nanotubes for use in additive manufacturing, metal injection molding, thermal spray, and hot isostatic pressing. It serves aviation, aerospace, medical, mining and drilling, energy storage, and microelectronics industries. The company was founded in 1990 and is headquartered in Sherbrooke, Canada.

Oslo Børs Benchmark Index_GI ended the session with TEKNA HOLDING jumping 4.56% to €5.96 on Monday, after five consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI dropped 0.16% to €1,416.45, after five consecutive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, TEKNA HOLDING has a trailing twelve months EPS of kr-0.95.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.75%.

More news about TEKNA HOLDING.

6. NYXOAH (NYXH.BR)

4.42% Price Change

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with NYXOAH jumping 4.42% to €8.50 on Monday while BEL 20 dropped 0.82% to €3,980.58.

Earnings Per Share

As for profitability, NYXOAH has a trailing twelve months EPS of €-1.54.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.58%.

Yearly Top and Bottom Value

NYXOAH’s stock is valued at €8.50 at 22:40 EST, way below its 52-week high of €17.60 and way higher than its 52-week low of €3.79.

Volatility

NYXOAH’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.34%, a negative 0.90%, and a positive 5.15%.

NYXOAH’s highest amplitude of average volatility was 3.29% (last week), 4.46% (last month), and 5.15% (last quarter).

Moving Average

NYXOAH’s value is way below its 50-day moving average of €11.55 and higher than its 200-day moving average of €7.87.

Revenue Growth

Year-on-year quarterly revenue growth grew by 39.6%, now sitting on 4.35M for the twelve trailing months.

More news about NYXOAH.

7. MPC CONTAINER SHIP (MPCC.OL)

4.09% Price Change

MPC Container Ships ASA owns and operates a portfolio of container vessels. The company focuses on small-to mid-size vessels that are chartered out on time-charter contracts to global and regional liner shipping companies serving intra-regional trade lanes. It operates a fleet of 59 vessels with an aggregate capacity of approximately 126,943 twenty-foot equivalent units. The company was incorporated in 2017 and is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with MPC CONTAINER SHIP rising 4.09% to €19.73 on Monday, after three successive sessions in a row of gains. Oslo Børs Benchmark Index_GI fell 0.16% to €1,416.45, after five sequential sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, MPC CONTAINER SHIP has a trailing twelve months EPS of kr7.96.

PE Ratio

MPC CONTAINER SHIP has a trailing twelve months price to earnings ratio of 2.48. Meaning, the purchaser of the share is investing kr2.48 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 44.09%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 5.7%, now sitting on 711.28M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MPC CONTAINER SHIP’s stock is considered to be oversold (<=20).

Sales Growth

MPC CONTAINER SHIP’s sales growth is negative 15.7% for the present quarter and negative 39.4% for the next.

Yearly Top and Bottom Value

MPC CONTAINER SHIP’s stock is valued at kr19.73 at 22:40 EST, below its 52-week high of kr21.38 and way above its 52-week low of kr11.60.

More news about MPC CONTAINER SHIP.

8. BEVER HOLDING (BEVER.AS)

4.07% Price Change

Bever Holding NV operates as a real estate company in the Netherlands and Belgium. The company develops residential and non-residential properties. It also invests in, acquires, and leases real estate properties. The company was incorporated in 1975 and is based in Wassenaar, the Netherlands.

AEX-Index ended the session with BEVER HOLDING jumping 4.07% to €2.56 on Monday while AEX-Index rose 0.14% to €911.91.

Earnings Per Share

As for profitability, BEVER HOLDING has a trailing twelve months EPS of €0.35.

PE Ratio

BEVER HOLDING has a trailing twelve months price to earnings ratio of 7.31. Meaning, the purchaser of the share is investing €7.31 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -47.79%.

More news about BEVER HOLDING.

9. ULTIMOVACS (ULTI.OL)

4.04% Price Change

Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with ULTIMOVACS jumping 4.04% to €7.21 on Monday, after three successive sessions in a row of losses. Oslo Børs Benchmark Index_GI slid 0.16% to €1,416.45, after five sequential sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, ULTIMOVACS has a trailing twelve months EPS of kr-5.5.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.94%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ULTIMOVACS’s stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

ULTIMOVACS’s stock is valued at kr7.21 at 22:40 EST, way below its 52-week high of kr178.60 and way higher than its 52-week low of kr6.07.

Volume

Today’s last reported volume for ULTIMOVACS is 164437 which is 90.14% below its average volume of 1668630.

Moving Average

ULTIMOVACS’s value is way under its 50-day moving average of kr33.11 and way below its 200-day moving average of kr88.30.

More news about ULTIMOVACS.

10. DGB GROUP N.V. (DGB.AS)

3.92% Price Change

DGB Group N.V. invests in, develops, and manages carbon credits and biodiversity projects for businesses and governments in the Netherlands and internationally. The company offers nature-based solutions comprising removing or avoiding carbon emissions, tackling social, and environmental challenges; manages projects that focuses on ecosystem restoration, habitat conservation, and biodiversity enrichment; and undertakes plastic projects, which consists of removing and recycling plastic, waste reduction, and environmental conservation works, as well as carbon offsetting projects for reducing carbon footprint of companies. It also provides ESG reporting and tree integration services. The company was formerly known as Verenigde Nederlandse Compagnie N.V. and changed its name to DGB Group N.V. in January 2018. DGB Group N.V. was founded in 1957 and is based in Haarlemmermeer, the Netherlands.

AEX-Index ended the session with DGB GROUP N.V. jumping 3.92% to €0.53 on Monday while AEX-Index jumped 0.14% to €911.91.

Earnings Per Share

As for profitability, DGB GROUP N.V. has a trailing twelve months EPS of €-0.15.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.73%.

More news about DGB GROUP N.V..

Losers Today

1. NAI ORD SHARES (NAI.AS)

-9.78% Price Change

New Amsterdam Invest N.V. focuses on acquiring a stake in company active as an operating company in the real estate sector primarily in Europe and the United States. The company was incorporated in 2021 and is based in Amsterdam, the Netherlands.

AEX-Index ended the session with NAI ORD SHARES falling 9.78% to €8.30 on Monday, after three sequential sessions in a row of losses. AEX-Index jumped 0.14% to €911.91, after two sequential sessions in a row of gains, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, NAI ORD SHARES has a trailing twelve months EPS of €-0.67.

Yearly Top and Bottom Value

NAI ORD SHARES’s stock is valued at €8.30 at 22:40 EST, way below its 52-week high of €11.00 and way higher than its 52-week low of €6.90.

Volatility

NAI ORD SHARES’s last week, last month’s, and last quarter’s current intraday variation average was 2.62%, 0.20%, and 2.81%.

NAI ORD SHARES’s highest amplitude of average volatility was 4.25% (last week), 3.67% (last month), and 2.81% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NAI ORD SHARES’s stock is considered to be overbought (>=80).

More news about NAI ORD SHARES.

2. PROSAFE (PRS.OL)

-8.05% Price Change

Prosafe SE, together with its subsidiaries, owns and operates semi-submersible accommodation vessels in South America, north America, and Europe. It is also involved in the maintenance and modification of installations on fields for the production, hook-up and commissioning of new fields, tiebacks to existing infrastructure, and decommissioning activities. The company owns and operates a fleet of six semi-submersible accommodation vessels and one tender support vessel. It primarily serves oil and gas industries. Prosafe SE was founded in 1972 and is headquartered in Stavanger, Norway.

Oslo Børs Benchmark Index_GI ended the session with PROSAFE dropping 8.05% to €30.85 on Monday, after two successive sessions in a row of losses. Oslo Børs Benchmark Index_GI slid 0.16% to €1,416.45, after five consecutive sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, PROSAFE has a trailing twelve months EPS of kr-65.02.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -190.72%.

Volume

Today’s last reported volume for PROSAFE is 137022 which is 126.38% above its average volume of 60526.

Moving Average

PROSAFE’s worth is way under its 50-day moving average of kr45.76 and way under its 200-day moving average of kr65.34.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is 75.8% and a drop 16.1% for the next.

More news about PROSAFE.

3. NEPI ROCKCASTLE (NRP.AS)

-6.15% Price Change

NEPI Rockcastle N.V. (“the Company”, “NEPI Rockcastle”, “the Group”) is a public limited company domiciled in the Netherlands, having its registered office at Strawinskylaan 563, WTC Zuidas, Tower Ten, 5th Floor, 1077 XX Amsterdam, with registration number at the Dutch Chamber of Commerce 87488329. The Company's shares are listed on the Main Board of the Johannesburg Stock Exchange Limited (“JSE”), Euronext Amsterdam and A2X. NEPI Rockcastle is the premier owner and operator of shopping centres in Central and Eastern Europe (“CEE”). The Group benefits from a highly-skilled internal management team which combines asset management, development, investment, leasing and financial expertise.

AEX-Index ended the session with NEPI ROCKCASTLE dropping 6.15% to €6.10 on Monday while AEX-Index rose 0.14% to €911.91.

Earnings Per Share

As for profitability, NEPI ROCKCASTLE has a trailing twelve months EPS of €0.75.

PE Ratio

NEPI ROCKCASTLE has a trailing twelve months price to earnings ratio of 8.13. Meaning, the purchaser of the share is investing €8.13 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.62%.

Volume

Today’s last reported volume for NEPI ROCKCASTLE is 182 which is 81.69% below its average volume of 994.

More news about NEPI ROCKCASTLE.

4. FUT.CLUBE PORTO (FCP.LS)

-5.88% Price Change

Futebol Clube do Porto – Futebol, S.A.D., together with its subsidiaries, participates in professional football competitions, and the sporting events promotion and organization in Portugal. It also engages in the image rights commercialization, sponsoring, merchandising, and products licensing activities; production, editing, and commercialization of multimedia material, as well as Internet, periodical, and non-periodical publications; and sport equipment management and exploration business, as well as insurance broking activities. In addition, the company organizes and sells travel and tour packages; and tickets and seat reservations, as well as represents travel agencies and tourism. Further, it is involved in the concept, design, development, production, direction, promotion, marketing, acquisition, exploration rights, recording, distribution, and dissemination of works and audiovisual programs, multimedia, television, video, cinema, theme, Internet, channels, tourist events, and cultural and sporting in any formats and systems. Additionally, the company manages, operates, and provides services in the areas of recording, production, and communication of audiovisual works, television shows, sounds, images, and other audiovisuals; and edits periodic publicities, books, and multimedia. It also explores for the Porto Canal cable television channel; and produces and executes advertisings, news reports, documentaries, and TV programs in video support. The company was founded in 1893 and is headquartered in Porto, Portugal.

PSI ended the session with FUT.CLUBE PORTO sliding 5.88% to €1.60 on Monday, after two sequential sessions in a row of gains. PSI fell 0.58% to €6,871.86, after five sequential sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, FUT.CLUBE PORTO has a trailing twelve months EPS of €-2.12.

Revenue Growth

Year-on-year quarterly revenue growth grew by 13.3%, now sitting on 155.82M for the twelve trailing months.

Volume

Today’s last reported volume for FUT.CLUBE PORTO is 351 which is 1.68% below its average volume of 357.

More news about FUT.CLUBE PORTO.

5. ARCTICZYMES TECHNO (AZT.OL)

-5.86% Price Change

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing. It offers salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. It operates in Norway, Germany, Lithuania, Italy, other countries in Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.

Oslo Børs Benchmark Index_GI ended the session with ARCTICZYMES TECHNO dropping 5.86% to €22.50 on Monday while Oslo Børs Benchmark Index_GI slid 0.16% to €1,416.45.

Earnings Per Share

As for profitability, ARCTICZYMES TECHNO has a trailing twelve months EPS of kr0.38.

PE Ratio

ARCTICZYMES TECHNO has a trailing twelve months price to earnings ratio of 59.21. Meaning, the purchaser of the share is investing kr59.21 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.15%.

Volatility

ARCTICZYMES TECHNO’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.16%, a negative 1.01%, and a positive 2.39%.

ARCTICZYMES TECHNO’s highest amplitude of average volatility was 2.58% (last week), 1.77% (last month), and 2.39% (last quarter).

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 100% and 650%, respectively.

Volume

Today’s last reported volume for ARCTICZYMES TECHNO is 56696 which is 76.39% above its average volume of 32142.

Sales Growth

ARCTICZYMES TECHNO’s sales growth is 5.8% for the ongoing quarter and 45.6% for the next.

More news about ARCTICZYMES TECHNO.

6. BERGENBIO (BGBIO.OL)

-5.62% Price Change

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Oslo Børs Benchmark Index_GI ended the session with BERGENBIO sliding 5.62% to €0.13 on Monday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI fell 0.16% to €1,416.45, after five successive sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, BERGENBIO has a trailing twelve months EPS of kr-0.13.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -179.58%.

More news about BERGENBIO.

7. ADUX (ADUX.PA)

-4.64% Price Change

AdUX SA provides advertising services in France, Belgium, Italy, Spain, Germany, the Netherlands, and internationally. It provides non-intrusive advertising, in-content advertising, brand content, and geomarketing services. The company was founded in 1996 and is headquartered in Paris, France.

CAC 40 ended the session with ADUX falling 4.64% to €1.34 on Monday, after two successive sessions in a row of gains. CAC 40 slid 0.12% to €8,209.28, after five sequential sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, ADUX has a trailing twelve months EPS of €0.36.

PE Ratio

ADUX has a trailing twelve months price to earnings ratio of 3.71. Meaning, the purchaser of the share is investing €3.71 for every euro of annual earnings.

Revenue Growth

Year-on-year quarterly revenue growth declined by 7.2%, now sitting on 22.82M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ADUX’s stock is considered to be oversold (<=20).

Moving Average

ADUX’s value is way above its 50-day moving average of €1.17 and above its 200-day moving average of €1.32.

Yearly Top and Bottom Value

ADUX’s stock is valued at €1.34 at 22:40 EST, way below its 52-week high of €1.77 and way above its 52-week low of €0.99.

More news about ADUX.

8. INTEROIL EXPL PROD (IOX.OL)

-4.52% Price Change

Interoil Exploration and Production ASA, together with its subsidiaries, operates as an upstream oil exploration and production company. It engages in the acquisition, exploration, development, and operation of oil and natural gas properties. The company's portfolio includes two producing concessions and two exploration concessions in Colombia; and one exploration and seven production concessions in Argentina. Interoil Exploration and Production ASA was incorporated in 2005 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with INTEROIL EXPL PROD dropping 4.52% to €1.90 on Monday while Oslo Børs Benchmark Index_GI dropped 0.16% to €1,416.45.

Earnings Per Share

As for profitability, INTEROIL EXPL PROD has a trailing twelve months EPS of kr-4.05.

Revenue Growth

Year-on-year quarterly revenue growth grew by 94.4%, now sitting on 23.92M for the twelve trailing months.

Volatility

INTEROIL EXPL PROD’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.88%, a negative 1.70%, and a positive 2.83%.

INTEROIL EXPL PROD’s highest amplitude of average volatility was 3.66% (last week), 3.29% (last month), and 2.83% (last quarter).

More news about INTEROIL EXPL PROD.

9. VISTIN PHARMA (VISTN.OL)

-4.24% Price Change

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with VISTIN PHARMA dropping 4.24% to €22.60 on Monday, after two sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI dropped 0.16% to €1,416.45, after five successive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.27.

PE Ratio

VISTIN PHARMA has a trailing twelve months price to earnings ratio of 17.8. Meaning, the purchaser of the share is investing kr17.8 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.84%.

Moving Average

VISTIN PHARMA’s worth is under its 50-day moving average of kr23.01 and below its 200-day moving average of kr23.04.

More news about VISTIN PHARMA.

10. EDP (EDP.LS)

-4.08% Price Change

EDP – Energias de Portugal, S.A. engages in the generation, transmission, distribution, and supply of electricity in Portugal, Spain, France, Poland, Romania, Italy, Belgium, the United Kingdom, Greece, Colombia, Brazil, North America, and internationally. It operates through Renewables, Networks, and Client Solutions & Energy Management segments. The company primarily generates and sells electricity through hydro, CCGT, coal, wind, solar, nuclear, and cogeneration and waste sources. It has an installed capacity of 28 GW; and operates 380,788 kilometers of distribution network lines. The company is also involved in the supply of natural gas. In addition, it offers engineering, laboratory tests, professional training, and energy services, as well as property management services. The company's electricity and gas customers include domestic, industrial, commercial, agricultural, and others. The company was incorporated in 1976 and is headquartered in Lisbon, Portugal.

PSI ended the session with EDP sliding 4.08% to €3.69 on Monday, after four sequential sessions in a row of gains. PSI fell 0.58% to €6,871.86, after five sequential sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, EDP has a trailing twelve months EPS of €0.23.

PE Ratio

EDP has a trailing twelve months price to earnings ratio of 16.04. Meaning, the purchaser of the share is investing €16.04 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.73%.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on May 6, 2024, the estimated forward annual dividend rate is 0.2 and the estimated forward annual dividend yield is 5.37%.

Sales Growth

EDP’s sales growth is negative 7.7% for the ongoing quarter and negative 7.7% for the next.

Volatility

EDP’s last week, last month’s, and last quarter’s current intraday variation average was 2.33%, 0.33%, and 1.36%.

EDP’s highest amplitude of average volatility was 2.33% (last week), 1.58% (last month), and 1.36% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth declined by 17.9%, now sitting on 16.2B for the twelve trailing months.

More news about EDP.

Stay up to date with our winners and losers daily report